Healthcare costs in America are seeping into nonhealthcare companies’ earnings announcements. None of those companies discussed healthcare this time last year.
Healthcare costs in America are seeping into nonhealthcare companies’ earnings announcements. The list from a cursory search of one recent week’s public company earnings transcripts includes firms that sell sneakers and tennis rackets, make the dressing for your Caesar salad, deliver flowers to your sweetheart, and provide services to oil companies.
None of those companies discussed healthcare this time last year. It may be too early to it call a trend but it’s worth noting.
The negative press of outlier expenses, and a renewed focus on what does or doesn’t work, may lead to some improvement. Below is a summary of what the companies reported:
As a top 3 or 4 expense, nonhealthcare companies rarely discuss healthcare costs with investors. It’s hidden within the SG&A line of the income statement. Brokers, vendors, and consultants have been inconsistent with delivering solutions. Usually their interests are not aligned and it’s a tough battle. Inflation, demographic changes, regulation, and innovation have pressured budgets. Costs of $8000 to $12,000 per employee in the United States is just the price of doing business. Healthcare trend of 2 to 3 times the consumer price index is the benchmark and is set in budgets. Breaking that has not been something companies have consistently reported or reliably bragged about.
Many in the healthcare industry lament the lack of attention the C-suite places on healthcare purchasing decisions. Some say it as if companies don’t like saving money. In reality, they’re focused on capital allocation, strategy, debt structure, and whether to open a new plant in Poland, and they are fatigued by the failed promises of big savings from vendors and consultants. What’s more, for technology companies with young employees, the low employee cost share, higher dollar benefits, and low hassle are the best decision since they keep employees happy and focused.
Chief Financial Officers will start caring about healthcare, viewing it as something more than a commodity, when it becomes something they can consistently impact, is something employees want, and delivers a meaningful return on investment. One-off case studies don’t help. They want unbiased results. Ironically, this is not likely to happen by following “best practices” surveys. As British economist John Maynard Keynes said: “Worldly wisdom teaches that it is better for reputation to fail conventionally than to succeed unconventionally.”
What can be done? Game theory could call for less and with a delicate balance on employee impact. Tenure is dropping in many industries, and investments in health programs may see results accrue to the next company. I suggest you Google “Al Lewis Quizzify.” All the poking and prodding and forced wellness is not helping, and it costs hundreds of dollars per employee per year when you add incentives (bribes). There’s also a bias to buy more. If brokers or consultants don’t ask you to buy something shiny and new they’re not “doing their jobs,” but it’s debatable how much value they’re adding.
Ideas need deeper consideration of second and third order consequences. Increased access tends to lead to increased use. For example, 90% of companies now offer telemedicine, only about 1 in 20 use it per year, yet it costs as much per visit as primary care and is silent on the evidence of the total emergency room reduction needed to justify published savings. Reducing friction to drive care to cheaper and higher quality settings helps, too. Walmart contracts with proven Centers of Excellence for certain procedures related to joints, spines, cardiovascular, cancer, and more. Improved healthcare and financial literacy are also things we all need in regular doses.
Does it move a stock or warrant mentioning to investors? That will be a benchmark. That’s when companies will consistently care. Cutting wasteful programs and doing the opposite of what many helpers say are great starts. A famous Seinfeld episode finds George Costanza questioning his purpose and instincts. He soon realizes that if he does the opposite, he’ll get out of his funk. More companies need to follow that wisdom. Perhaps that will lead to consistently higher earnings.
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Collecting SDOH Data Can Assess Risk of Medical Nonadherence, Improve HEI and Star Ratings
April 18th 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, a panel of presenters explored changes coming to Medicare that incorporate social determinants of health (SDOH) data to improve patient and health system outcomes.
Read More
Many Patients With Psoriasis in Clinical Trials Experience Nocebo Effects, Study Finds
April 18th 2024Half of patients exposed to placebo in clinical trials experienced adverse events (AEs), which may be partially explainable by nocebo effects, according to a recent review and meta-analysis.
Read More